ultibro breezhaler 110/50 indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule
novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); indacaterol maleate, quantity: 143 microgram (equivalent: indacaterol, qty 110 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - ultibro breezhaler 110/50 is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd), and for the reduction of exacerbations of copd in patients with a history of exacerbations.
ultibro breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules
novartis europharm limited - indacaterol, glycopyrronium bromide - inhalation powder, hard capsule - 110 microgram indacaterol and 50 microgram glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)
xoterna breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules
novartis europharm limited - indacaterol, glycopyrronium - inhalation powder, hard capsule - 85 micrograms/43 micrograms - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)
atectura breezhaler 125/260 indacaterol (as acetate)/mometasone furoate 125/260 microgram powder for inhalation in hard capsule with inhaler
novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 320 microgram - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
enerzair breezhaler 114/46/136 indacaterol/glycopyrronium/mometasone furoate 114/46/136 microgram powder for inhalation in capsule with inhaler
novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 160 microgram; glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
enerzair breezhaler 114/46/68 indacaterol/glycopyrronium/mometasone furoate 114/46/68 microgram powder for inhalation in capsule with inhaler
novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
signifor pasireotide 300 microgram/1 ml (as diaspartate) solution for injection ampoule
recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.
onbrez breezhaler indacaterol maleate 300 microgram hard capsule for inhalation
novartis pharmaceuticals australia pty ltd - indacaterol maleate, quantity: 389 microgram (equivalent: indacaterol, qty 300 microgram) - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; brilliant blue fcf aluminium lake; industrial methylated spirit; iron oxide black; ethanol; shellac; strong ammonia solution; sulfuric acid - onbrez breezhaler is a long-acting beta2-agonist indicated for long-term, once-daily, maintenance bronchodilator treatment of airflow limitation in patients with chronic obstructive pulmonary disease (copd).
onbrez breezhaler indacaterol maleate 150 microgram hard capsule for inhalation
novartis pharmaceuticals australia pty ltd - indacaterol maleate, quantity: 194 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - onbrez breezhaler is a long-acting beta2-agonist indicated for long-term, once-daily, maintenance bronchodilator treatment of airflow limitation in patients with chronic obstructive pulmonary disease (copd).
zoreeda 25 microgram/125 microgram per actuation pressurised inhalation, suspension
cipla europe nv - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone